Partner Ingrid Vandenborre reviews Italy’s Competition Authority's finding that Aspen Pharmacare engaged in excessive and unfair pricing in relation to four oncology products, concluding that the regulator skipped the unfairness analysis set out by European Court of Justice in United Brands.
The Aspen Italy Decision: A "Quick Look" Assessment Leaves Open Questions
Global Competition Review